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Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) remodel the pericellular environment by
regulating the cleavage of extracellular matrix proteins, cell surface components, neurotransmitter receptors, and growth factors
that mediate cell adhesion, synaptogenesis, synaptic plasticity, and long-term potentiation. Interestingly, increased MMP activity
and dysregulation of the balance between MMPs and TIMPs have also been implicated in various pathologic conditions. In this
paper, we discuss various animal models that suggest that the activation of the gelatinases MMP-2 and MMP-9 is involved in
pathogenesis of drug dependence, Alzheimer’s disease, and epilepsy.
1.Introduction
Matrix metalloproteinases (MMPs) function to remodel the
pericellular environment, primarily by cleaving extracellular
matrix (ECM) proteins [1]. This family of enzymes contains
more than 20 members, all of which require Zn2+ for their
enzymatic activities. Several MMPs, including all of the
membrane-anchored versions, contain a furin motif (MMP-
11, MMP-14, MMP-15, and MMP-16, among others) that
mediates intracellular activation of the proteinase prior to its
appearance outside of the cell. The activation of the other
MMPs requires extracellular proteolytic processing of the
secreted zymogens into the active enzymes, a process per-
formed by MMPs or speciﬁc proteinases [2, 3].
MMP activity is regulated by interactions with tissue
inhibitors of metalloproteinases (TIMPs), a family of mul-
tifunctional secreted proteins (TIMP-1–4) that promote
growth and regulate the cell cycle in various cell types [1, 4].
Regional and cell-speciﬁc expression of MMPs and TIMPs
hasbeendetectedatvariousstagesofcerebellardevelopment,
whichmayberelatedtogranularcellmigration,arborization
of Purkinje cells, and synaptogenesis [5]. The regulation of
MMPs expression and activity appears to be a very com-
plex process [6]. The expression is regulated at the level
of transcription by a variety of growth factors, cytokines,
and chemokines although posttranscriptional and epigenetic
modiﬁcation may also contribute.
In an exemplary case of MMP-9, there are a number of
gene regulatory sequences driving the MMP-9 expression,
with AP1 and NF-κB being the most prominent. MMP-9 is
produced by cells in an inactive form. Fully active protein
is produced by disruption of the cysteine-zinc interaction
and enzymatic removal of the propeptide. The activation
of proenzyme is controlled by a cascade of steps involving
other MMP and the plasmin system. Pro-MMP-9 can form
a complex with TIMP-1, which involves interaction of the
C-terminal (noninhibitory) domain of pro-MMP-9 and the
C-terminal (noninhibitory) domain of TIMP-1. Moreover,2 Biochemistry Research International
low-density receptor-related protein can act as a receptor for
MMP-9, which mediates internalization and degradation of
the enzyme.
Of note, extensive cellular migration and remodeling
of the ECM are necessary for neural development [7]. It
was recently demonstrated that neuronal TIMP-1 [8, 9]a n d
MMP-9 [10] are regulated by synaptic activity, suggesting
that the balance between MMPs and TIMPs contributes
to activity-dependent reorganization of the neuronal archi-
tecture and synaptic physiology. Additionally, MMPs and
TIMPs modulate pathophysiologic functional and structural
remodeling of the cellular architecture, primarily by regu-
lating the cleavage of ECM proteins, the bioavailability of
growth factors and cytokines, and shedding of membrane
receptors [1, 3]. Indeed, MMPs have been linked to various
pathologic conditions of the central nervous system (CNS),
including ischemia, Alzheimer’s disease, multiple sclerosis,
Parkinson’s disease, and malignant glioma. In particular,
altered regulation of MMP-2 and MMP-9 has been linked
to several nervous system disorders [1]. Therefore, studies of
MMPs as key enzymes in both normal and abnormal brain
functioning represent a rapidly emerging ﬁeld.
Keeping these background in mind, we have been inves-
tigating the physiologic and pathophysiologic roles for
MMP/TIMP in learning and memory, drug dependence, Al-
zheimer’s disease, and epilepsy. In this paper, we discuss pot-
ential roles of MMPs—especially MMP-2 and MMP-9—in
physiologic and pathophysiologic neural processes.
2. MMPs in Emotion and Memory
MMP-9 expression is upregulated, and the protein becomes
proteolytically active during the maintenance phase of long-
term potentiation (LTP) at CA3–CA1 synapses in the hip-
pocampus [11]. Conversely, TIMP-1 abolishes MMP-9-de-
pendent long-lasting LTP in the prefrontal cortex [12]. These
reportssuggestaroleforMMP-9/TIMP-1systeminneuronal
plasticity such as LTP and memory.
FN-439, a broad-spectrum metalloproteinase inhibitor,
disrupts reconsolidation of fear memories, which is related
to emotionality in a reactivation-dependent manner [13].
Infusing an MMP inhibitor into the dorsal hippocampus
disrupted acquisition of spatial memory during the Morris’s
water maze test [14]. Hippocampal MMP-9 expression tran-
siently increased during memory acquisition in water maze
tests, and inhibition of MMP activity with MMP-9 antisense
oligonucleotides and an MMP inhibitor altered long-term
potentiation and prevented the acquisition of spatial mem-
ories during the Morris’s water maze test [15]. Conversely,
TIMP-1-deﬁcient mice fail to acquire an odor-conditioned
learning task, suggesting that the disruption of MMP/TIMP
balance disrupt physiologic function such as learning [16].
Interestingly, tissue plasminogen activator and MMPs are
also associated with anxiety-like behavior and memory for-
mation, with some studies demonstrating that tissue plas-
minogen activator in the amygdala promoted stress-induced
synaptic plasticity and anxiety-like behavior [17, 18]. Thus,
expression of these proteases may be critical for emotion and
Table 1: Summary of behavioral changes related to emotional






O u t e rs e c t o rc r o s s i n g ±±
Inner sector crossing ±±
Time in inner sector ±±
Number of rearing ⇑±




Time in open arm ⇑±
Open arm entries ⇑±
Time in closed arm ⇓±
Closed arm entries ±±
Behavioral changes in MMP-9(−/−) mice indicate that endogenous MMP-9
play a role in emotional behaviors.
±:n oc h a n g e ;⇑: signiﬁcant increase versus wild-type mice; ⇓: signiﬁcant
decrease versus wild-type mice. Modiﬁed from Mizoguchi et al. [21].
memory, and deletion of MMPs in mice may induce abnor-
malities in behavioral tests.
On the other hand, activity-dependent changes in the
ECM are thought to alter synaptic architecture and physiol-
ogy such that the eﬃciency of synaptic transmission is aﬀect-
ed. A recent study identiﬁed MMP-9 as a physiologic regula-
tor of N-methyl-D-aspartate (NMDA) receptor-dependent
synaptic plasticity and memory. These eﬀects of MMP-9 on
NMDA receptors are not mediated by changes in the over-
all ECM structure or direct cleavage of NMDA receptor sub-
units, but rather involve an integrin β1-dependent pathway
[19]. NMDA receptors are important mediators of synaptic
plasticity that are central to the neurobiological underpin-
nings of emotionality, learning, and memory [20]. Thus,
MMPs may play critical roles in emotion and memory by ex-
tracellularly regulating NMDA receptor signaling.
2.1. Emotional and Cognitive Behavioral Phenotypes in MMP-
2(−/−) and MMP-9(−/−) Mice. We investigated the roles of
MMP-2 and MMP-9 in emotional and cognitive function
using mice with targeted deletions of the MMP-2 or MMP-
9 genes [21]. Emotional changes in MMP-2(−/−) manifested
as more frequent rearing in the open-ﬁeld test and increased
time in the open arms and more open arm entries in the
elevated plus-arm maze test. Unlike MMP-2(−/−) mice, when
MMP-9(−/−) micewereexposedtomildlystressfulsituations,
they showed behavioral responses that indicated reduced
anxiety (Table 1). Thus, endogenous MMP-9 may contribute
to signaling pathways that modulate emotional behaviors.
MMP-9(−/−) micealsoshowedimpairedlong-termobject
recognition and fear memory, whereas spontaneous alterna-
tion behavior in the Y-maze test and short-term memory
were normal [21]. MMP-2(−/−) mice do not have any learn-
ing or memory phenotypes. These results suggest that MMP-
9 plays a role in the formation of long-term memories
but not short-term memories (Table 2). Furthermore, Nagy
et al. [11] showed that MMP-9 null-mutant mice displayedBiochemistry Research International 3
Table 2: Summary of impaired learning and memory parameters induced by MMP inhibition.
Test (type of memory) MMP inhibitor MMP-9(−/−) MMP-2(−/−)
Y-maze test (short-term memory) N.D. ±⇓
Novel-object recognition test (short-term object memory) N.D. ±±
Novel-object recognition test (long-term object memory) N.D. ⇓±
Conditioned fear memory test (long-term fear memory) ⇓⇓ ±
Morris’s water maze test (hippocampus-dependent spatial memory) ⇓ N.D. N.D.
Performance of MMP-9(−/−) mice in various memory test indicates impairments of long-term memory in the mutant mice.
±:n oc h a n g e ;⇓: signiﬁcant decrease versus control or wild-type mice; N.D.: not determined.
Modiﬁed from [13–15, 21].
Table 3: Changes in MMP and TIMP expression levels and activities induced by drugs of abuse.
Drug MMP-2 MMP-9 TIMP-2 MMP-3 Method (expression/activity) References
Methamphetamine (single treatment) ±±± N.D. mRNA/activity [32, 33]
Methamphetamine (repeated treatment) ⇑⇑⇑ N.D. mRNA/protein/activity [32, 33]
Cocaine N.D. ⇑ N.D. ± Activity [38]
Morphine ⇑ N.D. ⇑ N.D. Protein/activity Our unpublished data
Alcohol N.D. ⇑ N.D. N.D. Protein [39]
⇑⇑⇓ N.D. Protein/activity [40]
±:n oc h a n g e ;⇑: signiﬁcant increase versus control mice; N.D.: not determined.
a signiﬁcant deﬁcit in long-term hippocampus-dependent
memories for context conditioning but not cued condition-
ing. These results indicate that MMPs play critical roles in
synapticplasticityandhippocampal-dependentmemoryand
that inhibiting MMP activity may compromise the ability
of the dorsal hippocampus to reconﬁgure ECM molecules
and interfere with spatial memory acquisition. Although no
major defects in brain structures were observed with histo-
chemical examinations, it is possible that neuroadaptation
and compensatory mechanisms activated in response to tar-
sgeted deletions of MMP-2 and MMP-9 contributed to the
emotional and cognitive phenotypes in the mutant mice.
3. MMPs in Drug Dependence
Drug dependence is a complex phenomenon that, in some
cases, is mediated by neural plasticity and remodeling of
speciﬁc brain circuits after repeated exposure to a drug [22,
23]. For example, methamphetamine (METH), a commonly
abused drug, causes both acute and long-lasting eﬀects on
psychomotor behavior [24–26]; these eﬀects are associated
with increased extracellular dopamine levels in the brain,
owingtofacilitateddopaminereleasefrompresynapticnerve
terminalsandinhibiteddopaminereuptake[27].Thecellular
and molecular mechanisms underlying drug dependence are
thought to include processes similar to those operating in
other forms of synaptic plasticity, such as learning and mem-
ory [22, 23, 28]. Nevertheless, although repeated treatment
withcocaineoramphetaminesaltersneuralmorphologyand
synaptic connectivity in the mesolimbic system [29, 30], the
mechanisms underlying psychostimulant-induced remodel-
ing of synaptic structures have not been determined [31].
3.1. METH-Induced Changes in MMP and TIMP Expression
in the Brain. We demonstrated that repeated administration
of METH led to behavioral sensitization, which was accom-
panied by the induction of MMP-2, MMP-9, and TIMP-
2 expression in various regions of the brain, including the
frontal cortex and nucleus accumbens (NAc; Table 3)[ 32–
34]. Our data also showed that MMP-2 and MMP-9 were
expressed in neurons and glial cells. Repeated, but not single,
METH doses also induced TIMP-2 mRNA and protein
expression in neurons [32]. Previous studies also suggested
that the MMP/TIMP system is active in neuronal and glial
cells and that the expression levels and cellular localization
of these proteins are regulated according to developmental
and/or functional status of the brain [11, 35]. For instance,
during axonal extension, MMPs are located at growth cone
tips, where they mediate attachment and detachment of
neurons to the matrix substratum, whereas MMPs medi-
ate process extension in oligodendrocytes, suggesting that
the regulation of MMPs is an important component of
synaptogenesis [2]. Accordingly, MMP-2 and MMP-9 may
contribute to structural and functional alterations in the
brain following repeated exposure to METH.
3.2. Roles of the MMP/TIMP System in METH-Induced
Behavioral Sensitization and Reward. We demonstrated that
METH-induced behavioral sensitization and conditioned
place preference (CPP)—a measure of the rewarding eﬀect
of drugs—were markedly attenuated in MMP-2(−/−) and
MMP-9(−/−) mice compared with wild-type mice [33], and
doxycycline, inhibitor of MMP-2 and MMP-9, blocked
METH-induced behavioral sensitization and CPP (Table 4)
[32]. Antisense TIMP-2 oligonucleotides (TIMP-AS) inhib-4 Biochemistry Research International
Table 4: Summary of changes in addictive behaviors and dopamine release in response to inhibition of the MMP/TIMP system.
Test Drug TIMP-2-AS Doxycycline, FN-439
(MMP inhibitor) MMP-2(−/−) MMP-9(−/−) References
Hyperlocomotion
(single treatment) Methamphetamine ±±± ± [32, 33]
Locomotor sensitization




Methamphetamine N.D. ⇓⇓ ⇓ [32, 33]
Cocaine N.D. ⇓ N.D. N.D. [37]
Self-administration Alcohol N.D. ⇓ N.D. N.D. [41]
Dopamine release Methamphetamine ⇑⇓⇓ ⇓ [32, 33]
±:n oc h a n g e ;⇑: signiﬁcant increase versus control mice; ⇓: signiﬁcant decrease versus control mice; N.D.: not determined.
TIMP-2-AS: antisense TIMP-2 oligonucleotides.
ited METH-induced increases in TIMP-2 protein expression
and enhanced locomotor sensitization, eﬀects that were
associated with potentiation of METH-induced dopamine
release in the NAc (Table 4)[ 33]. Accordingly, a net increase
in MMP activity may be responsible, at least in part, for the
developmentofMETH-inducedbehavioralsensitizationand
structural and functional changes in the brain that underlie
METH dependence. Indeed, inhibiting MMPs altered func-
tional and structural correlations of deaﬀerentation-induced
sprouting,suchasremodelinginthedentategyrusofthehip-
pocampus[36].Interestingly,Brownetal.[37]demonstrated
that MMPs were involved in creating cocaine-associated
contextual memories and that reconsolidation of these
memories was disrupted by an MMP inhibitor. Further, the
authors showed that an MMP inhibitor impaired the expres-
sion of memory in response to a cocaine-associated cue after
extinction. In addition, elevated MMP-9 activity in the pre-
frontal cortex contributed to synaptic remodeling that was
important for the reactivation of a cocaine-related memory
or, alternatively, the modiﬁcation of a competing extinction
memory during reinstatement [38]. Moreover, MMP-9 is
elevated in serum of alcohol abusers [39], alcohol treatment
increased MMP-1, -2, and -9 activity, and decreased TIMP-
1 and -2 in the brain microvascular endothelial cells [40],
and inhibiting MMPs attenuated ethanol self-administration
[41]. These reports suggest that MMPs may also have a cru-
cial role in drug-associated memory. Because the neurologic
underpinningsoflearningandmemoryarecloselytiedtothe
development of aberrant behaviors related to drug abuse and
addiction [22, 23, 28], MMP-2 and MMP-9 expression may
be critical in the acquisition of METH-induced CPP.
Recently,itwasreportedthatMMP-9expressiondoesnot
aﬀect METH-induced neurotoxicity and instead contributes
to neural remodeling [42]. Further, Conant et al. [43]d e m -
onstrated that METH induced ICAM-5 cleavage in murine
hippocampus and striatum, which was accompanied by in-
creased MMP-9 protein levels. The authors also showed that
the N-terminal ICAM-5 ectodomain stimulated phosphory-
lation of coﬁlin via an integrin β1-dependent mechanism
that was linked to spine maturation. Although additional
studies are necessary, these data implicate MMPs in synaptic
plasticity associated with drug dependence.
3.3.RolesoftheMMP/TIMPSysteminDopamineNeurotrans-
mission. Behavioral changes induced by METH are linked to
its capacity to elevate extracellular dopamine levels by redis-
tributing dopamine from synaptic vesicles to the cytosol
and promoting reverse transport [44, 45]. METH-induced
behavioral sensitization is associated with enhanced METH-
induced increases in extracellular dopamine levels in the
NAc [27, 45]. Compared with wild-type mice, MMP-2(−/−)
and MMP-9(−/−) mice showed attenuated METH-induced
dopamine release in the NAc, behavioral sensitization, and
CPP [33]. Sensitization of METH-induced dopamine release
in the NAc was enhanced and reduced by TIMP-AS and
inhibitors of MMP-2 and MMP-9, respectively. In contrast,
infusion of puriﬁed human MMP-2 into the NAc signiﬁ-
cantly potentiated METH-increased dopamine release [32].
Reduced [3H]dopamine uptake into striatal synaptosomes
was observed in wild-type mice after repeated METH treat-
ment, whereas these changes were signiﬁcantly attenuated in
MMP-2(−/−) and MMP-9(−/−) mice [33]. Reverse activation
and internalization of plasmalemmal dopamine transporter
are involved in METH-induced increases in extracellular
dopamine levels [44, 46]. These results suggest that MMP-
2 and MMP-9 play crucial roles in METH-induced behav-
ioral sensitization and reward by regulating METH-induced
dopamine release and uptake via dopamine transporters in
the NAc.
The sensitivity of dopamine receptors to endogenous
and exogenous ligands is an important factor in physiologic
and pathologic dopamine neurotransmission, and reduced
signaling via dopamine D2 receptors may be an important
neuroadaptation in cocaine addiction [47]. G protein signal-
ing in the frontal cortex may play a crucial patholog-
ic role in cocaine sensitization and drug seeking [48]. We
have also shown that dopamine receptor agonist-stim-
ulated [35S]GTPγS binding is reduced in the frontal cortex
of rats sensitized to METH. TIMP-AS and an MMP-2/
MMP-9 inhibitor, respectively, potentiated and attenuatedBiochemistry Research International 5
Table 5: MMP protein expression in the brains of patients with
Alzheimer’s disease.
MMP Cell types References
MMP-2 Blood vessels and white matter glia [63, 64]
MMP-3 Neuron and occasional plaque [64]
MMP-9 Neuron, neuroﬁbrillary tangle,
plaque, and vessel wall [62–65]
the reduction in dopamine D2 receptor agonist-stimu-
lated [35S]GTPγS binding. Repeated METH treatment also
reduced dopamine D2 receptor agonist-stimulated
[35S]GTPγS binding in wild-type mice, whereas these chan-
ges were signiﬁcantly attenuated in MMP-2(−/−) and
MMP-9(−/−) mice [32]. These results suggest that MMPs
and TIMPs are involved in METH-induced dysregulation of
dopamine release and receptor signaling. Because dopamine
D2 receptors function in feedback inhibition of dopamine
release [49, 50], downregulated signaling may enhance
METH-induced increases in extracellular dopamine levels.
4. MMPs inAlzheimer’s Disease
Alzheimer’s disease is characterized by the deterioration of
cognitive and mental function. The pathology of Alzheimer’s
disease involves the formation of extracellular deposits of
amyloid beta (Aβ) peptide, leading to neuritic plaques and
neuroﬁbrillary tangles in the cortex and hippocampus [51,
52]. The neurotoxicity of Aβ has been clearly demonstrated
in vitro and in vivo and shown to involve oxidative stress,
perturbed intracellular calcium homeostasis, and activation
of apoptosis [53], and neural uptake of extracellular Aβ [54].
Intrahippocampal injections of Aβ, including Aβ1-40,
Aβ1-42,andAβ25-35,havebeenshowntoinducehippocam-
pal damage, learning and memory deﬁcits [55–57], and im-
pairment of the cholinergic system, which contribute to cog-
nitive deﬁcits associated with aging and neurodegenerative
diseases [58–60]. Whereas plaques and amyloid ﬁbrils are
thought to resist proteolytic degradation, certain proteases
may be involved in endogenous mechanisms that clear
plaques. A recent study showed that intracerebroventricu-
lar infusion of Aβ1-42 induced learning deﬁcits after 12
weeks in 9-month-old mice but not 2.5-month-old mice,
suggesting that Aβ infusion resulted in age-dependent and
delayed learning deﬁcits independent of Aβ deposition and
inﬂammation [61].
Interestingly, MMP-9 levels are increased in the brains of
patients with Alzheimer’s disease (Table 5)[ 62–65]. MMP-
9 is expressed in the cytoplasm of neurons, neuroﬁbrillary
tangles,senileplaques,andvascularwallsinbraintissuefrom
patients with Alzheimer’s disease [65]. Moreover, MMP-
9 expression is induced in astrocytes in the presence of
Aβ peptide [66]. Although MMP-9 cleaves the Aβ peptide
at several sites [62, 67], its role in Aβ-induced cognitive
dysfunction and neurotoxicity is unclear.
4.1. Aβ-Induced MMP Expression in the Brain. Previous
studyhasrevealedthatbothMMP-2andMMP-9areinduced
by the presence of Aβ [67] and highly expressed and secreted
by astrocytes [68, 69]. Accordingly, we investigated whether
MMP-2 and MMP-9 activities were induced by intracere-
broventricular injections of Aβ25-35 and Aβ1-40 using gel
zymography[70].Intracerebroventricularinjection ofAβ25-
35, Aβ1-40, or Aβ1-42 transiently and dose-dependently
increased hippocampal MMP-9 activity and protein expres-
sion, whereas MMP-2 was not aﬀected. The injection of a
control peptide, Aβ40-1, had no eﬀect on MMP-9 activity
and protein expression in the hippocampus, suggesting that
the induction of MMP-9 following intracerebroventricular
Aβ injection is not due to nonspeciﬁc response to brain
damage by the insertion of injection needle. Immunohisto-
chemistry revealed increased expression of MMP-9 in both
neurons and glial cells in the hippocampus after Aβ admin-
istration [70]. When gelatinase activity was analyzed in
thehippocampusfollowingintracerebroventricularinjection
of Aβ1-40 using in situ zymography, markedly increased
activity was detected in the hippocampal molecular layer
in the Aβ1-40-treated group compared with the Aβ40-1-
injected group [70].
M o r e o v e r ,w ef o u n dt h a tp r e t r e a t m e n tw i t hM K - 8 0 1
inhibited the Aβ-induced increase in MMP-9 expression,
indicating that activation of NMDA receptors is involved in
Aβ-induced expression of MMP-9 in vivo [70].
4.2. MMP Inhibition and Reduced Aβ-Induced Cognitive
Impairment and Neurotoxicity. Because MMP-9 has been
reported to cleave insoluble Aβ in vitro [67], it was thought
that MMP inhibitors may potentiate Aβ-induced cognitive
dysfunction and neurotoxicity. Our ﬁndings do not support
this concern, however. In fact, treatment with GM6001,
an MMP inhibitor, ameliorated Aβ-induced impairment
of recognition memory, suggesting that transient increases
in hippocampal MMP-9 activity are associated with the
development of Aβ-induced cognitive deﬁcits. The ﬁndings
obtained with a pharmacologic inhibitor were supported
by results showing that intracerebroventricular injection of
Aβ1-40 impaired recognition memory in wild-type mice
but not MMP-9(−/−) mice [70]. Therefore, even if MMP-
9d e g r a d e sA β or amyloid plaques, it may nonselectively
degrade ECM proteins and neural membranes, leading to
neuronal dysfunction and cognitive impairment.
Recent evidence has linked MMPs to various pathologic
conditions in the CNS, including ischemia, multiple sclero-
sis, Parkinson’s disease, and malignant glioma. This implies
that in addition to degrading ECM proteins, MMPs may
regulate cell death. In fact, recent studies have indicated that
MMP-9 has direct neurotoxic eﬀects [71]. We demonstrated
that MMP inhibitor II, which is reportedly highly selective
for MMP-2 and MMP-9 [72], blocks Aβ-induced release
of lactate dehydrogenase in primary cultured neurons,
indicating that MMP-9 contributes to Aβ-induced neuronal
cell death. Aβ-induced neurotoxicity was markedly reduced
in primary cultured cortical neurons from MMP-9(−/−)
mice compared with neurons from wild-type mice. These
results suggest that MMP-9 expression in the hippocampus
following Aβ1-40 infusion had a causal role in the resulting
neurotoxicity and cognitive impairment. On the basis of our6 Biochemistry Research International
Table 6: Summary of changes in brain MMP expression levels and activities induced by chemical stimulants.
Drug Dose (mg/kg) Seizure intensity MMP-2 MMP-9 Method (expression/activity) References
Pentylene-tetrazole
40 Ear and facial twitching ±± Activity [86]
40 Kindled seizure (tonic convulsion) ±⇑ Protein/activity [86]
60 Tonic convulsion ±± Activity [86]
50 Generalized seizures N.D. ⇑ mRNA [79]
Kainic acid
9-10 Tonic convulsion N.D. ⇑ Protein/activity [71, 83]
10 Status epilepticus N.D. ⇑ mRNA [80]
10 Convulsion ⇑⇑ Activity [82]
Pilocarpine 325 Status epilepticus ±⇑ Protein/activity [84]
Bicuculline 1.5–3.0 Convulsion ⇑⇑ Activity [82]
±:n oc h a n g e ;⇑: signiﬁcant increase versus control mice; N.D.: not determined.
ﬁndings,itisspeculatedthatAβ-inducedsecondarydysfunc-
tion such as MMP activation could result in learning deﬁcits
by impairing synaptic function in the hippocampus. Our
ﬁndings highlight the contribution of neural/glial MMP-9
to Aβ-induced neurotoxicity and cognitive impairment and
support the idea that for highly selective MMP-9, inhibitors
may reduce deleterious proteolytic activity and neuronal
death in Alzheimer’s disease.
5. MMPs inEpilepsy
Seizures cause brain injury via a number of mechanisms
that may contribute to neurologic and cognitive deﬁcits in
patients with epilepsy. Although seizures induce neuronal
death in some situations, they also produce nonlethal
pathophysiologic eﬀects on neuronal structures and func-
tions [73]. Kindling is an experimental epilepsy model in
which repeated electrical or chemical stimulation of certain
forebrain structures triggers progressively more intense
electroencephalographic and behavioral seizure activity [74–
76]. Once established, kindling results in a permanent state
of seizure susceptibility, which may manifest as spontaneous
epileptiform seizures [76, 77].
Serum MMP-9 levels and the ratio of MMP-9 to TIMP-1
areelevatedinchildrenwithvariousfebrileseizuresandcon-
vulsive status epilepticus [78]. Moreover, expression levels of
MMP-9 mRNA increased in response to neuronal depolar-
ization in the rat hippocampus [79], and MMP-9 mRNA was
transported to dendrites and synapses in the hippocampal
dentate gyrus of kainic acid-treated rats [80]. Jourquin et
al. [71] used organotypic cultures to demonstrate increased
release and activity of MMP-9 after stimulation with neu-
rotoxic kainate and reduced neuronal cell death following
MMP-9 inhibition. TIMP-1 mRNA is also increased in den-
tate gyrus following seizures, and elevated TIMP-1 mRNA
and protein are measured in the hippocampus with seizure
[8]. TIMPs are produced by microglia and astrocytes located
in cortex and white matter and may play a role in neural
regeneration depending upon the degree of expression and
the time since injury [81]. Although MMP-9/TIMP-1 is
e x p r e s s e di nr e s p o n s et on e u r a la c t i v i t yi ns o m em o d e l so f
epileptogenesis [82–85], the pathophysiologic and etiologic
rolesofthismetalloproteinase,includingpotentialmolecular
targets during kindling seizure development, are not clear.
5.1. MMPs in Kindled Seizure. Mice administered a single
pentylenetetrazole (PTZ) dose (20–40mg/kg) exhibit ear
and facial twitching or, at times, convulsive twitching
axially throughout the body. PTZ at a dose of 60mg/kg
induces seizures characterized by tonic convulsion, jumping,
and wild running. Repeated administration of PTZ at a
dose of 40mg/kg produces chemical kindling, a phenotype
associated with a progressive increase in the seizure score.
Repeated PTZ treatment increased MMP-9 expression in the
hippocampus for at least 24h after the ﬁnal dose (Table 6).
On the other hand, hippocampal MMP-9 levels were not
aﬀected in mice that showed convulsive seizures in response
to a single 60mg/kg PTZ dose. No changes in hippocampal
MMP-2 levels were detected following acute or repeated PTZ
treatment [86].
We investigated the role of MMP-9 in PTZ-induced
kindled seizure using MMP-9(−/−) mice. No diﬀerence in the
severity of tonic seizures induced by a single PTZ treatment
was observed between wild-type and MMP-9(−/−) mice.
Repeated PTZ treatment induced kindled seizure in wild-
type mice, whereas PTZ-treated MMP-9(−/−) mice showed
a marked delay in kindling development although pro-
gression of kindled seizure was eventually observed. These
results demonstrate that deletion of MMP-9 attenuated
PTZ-induced kindled seizure [86] and agreed with recent
ﬁndings showing that the synaptic pool of MMP-9 is a
critical determinant of seizure development [83]. We also
showed that mossy ﬁber sprouting induced by repeated
PTZ treatment was reduced in MMP-9(−/−) mice compared
with wild-type mice, suggesting that increased hippocampal
MMP-9 activity is associated with the sprouting of mossy
ﬁbers [86].
5.2. MMP-9-Mediated Maturation of Brain-Derived Neu-
rotrophic Factor and the Development of PTZ-Induced Kin-
dling. Brain-derived neurotrophic factor (BDNF) has been
shown to be a potent morphoregulator that controls axon
branching and activity-dependent reﬁnement of synapses
[87, 88]. BDNF also plays a role in epileptogenesis and
kindled seizure. A recent study showed that high-frequency
neuronal activity controlled the ratio of extracellular pro-
BDNF to mature BDNF by regulating the secretion of
extracellular proteases [89]. Of particular note for this paper,
proforms of neurotrophin are cleaved and activated byBiochemistry Research International 7
MMPs [2, 3, 90], and MMP-9 converts pro-BDNF to mature
BDNF, resulting in tropomyosin-related kinase B (TrkB)
activation [2, 91].
Repeated PTZ treatment increased BDNF mRNA and
protein levels in the hippocampi of kindled wild-type mice.
MMP-9(−/−) mice showed reduced levels of mature BDNF
during the early stage of kindling, which may explain slower
kindling development in the mutant animals. During the
later kindling stage, however, mature BDNF levels were
similar in MMP-9(−/−) and wild-type mice. These results
suggest that MMP-9 plays a role in kindling development by
converting pro-BDNF to mature BDNF in the hippocampus,
whereas other factors mediate BDNF maturation during
the later kindling stage. This may explain why the seizure
response curves for MMP-9(−/−) and wild-type mice diﬀered
more at the early stage than at the later stage of kindling [86].
To prove the assumption described above, the BDNF
scavenger TrkB-Fc was microinjected into the right ventricle
before each PTZ treatment. The treatment signiﬁcantly
suppressed the development of kindling in wild-type mice,
whereas no eﬀect was observed in MMP-9(−/−) mice. On
the other hand, bilateral injections of pro-BDNF into the
hippocampal dentate gyrus signiﬁcantly enhanced kindling
in wild-type mice but not MMP-9(−/−) mice. These ﬁndings
suggest that MMP-9 is involved in the progression of behav-
ioralphenotypesinkindledmiceowingtoconversionofpro-
BDNF to mature BDNF in the hippocampus. These results
likely reﬂect a relationship between MMP-9 expression and
mature BDNF levels in the development of PTZ-induced
kindling [86].
Extracellular BDNF stimulates TrkB receptors on the
hilar segment of the mossy ﬁber to induce axonal branching,
which may create hyperexcitable dentate circuits [92]. Thus,
PTZ-induced kindling may be aggravated through synaptic
transformation, including mossy ﬁber sprouting induced by
prolonged MMP-9 activation and subsequent increase in
mature BDNF levels. These ﬁndings suggest the contribution
of neural/glial MMP-9 to epileptogenesis via its activity on
extracellular macromolecules such as BDNF.
6. Conclusion
As reviewed in this paper, research has begun to elucidate
the roles of MMPs in physiologic processes and acute and
chronic CNS disorders. Proteolytic mechanisms regulate
various developmental and homeostatic processes, whereas
inappropriate proteolysis causes or exacerbates a number of
CNS disorders. Our previous studies suggest that MMP-9
plays a role in emotional and cognitive behaviors, which may
be related to activity-dependent synaptic plasticity and brain
development. Furthermore, MMP-9 expression appears to
playacrucialroleinMETH-inducedbehavioralsensitization
by modulating the function of such plasma membrane
proteins as dopamine receptors and transporters. MMP-9
also contributes to Aβ-induced neuronal dysfunction and
cognitive impairment by nonspeciﬁcally destroying the ex-
tracellular matrix and neural membranes. Finally, MMP-9
is involved in the progression of behavioral phenotypes in
kindled mice by converting pro-BDNF to mature BDNF in
the hippocampus. These results suggest that MMP overex-
pression is associated with structural and functional changes
in the cerebral cortex and mesocorticolimbic system, leading
to abnormal behaviors following drug treatment. In addition
to contributions to various diseases, MMPs have many
physiologic roles in such processes as neurogenesis related to
memory formation and emotion. More research is needed
to understand the diverse roles of these proteases and their
potential as therapeutic targets.
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